• Explore /
  • Poster
  • / A single-arm, open-label, phase II study to evaluate the safety of vemurafenib (VEM) followed by ipilimumab (IPI) in BRAF V600-mutated metastatic melanoma (MM).

A single-arm, open-label, phase II study to evaluate the safety of vemurafenib (VEM) followed by ipilimumab (IPI) in BRAF V600-mutated metastatic melanoma (MM).

Abstract Poster

Authors

null

Asim Amin

Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC

Asim Amin , David H. Lawson , April K. Salama , Henry B. Koon , Troy H. Guthrie , Sajeve Samuel Thomas , Steven O'Day , Montaser F. Shaheen , Bin Zhang , Stephen Francis , F. Stephen Hodi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Melanoma/Skin Cancers

Clinical Trial Registration Number

NCT01673854

Citation

J Clin Oncol 33, 2015 (suppl; abstr 9032)

DOI

10.1200/jco.2015.33.15_suppl.9032

Abstract #

9032

Poster Bd #

275

Abstract Disclosures

Similar Posters

First Author: F. Stephen Hodi

First Author: Martin H. Schuler

First Author: Antoni Ribas

First Author: Rahima Jamal